Evidence map›Paper›PMID 33106388›Full record

ArticleNeurology2021

Association of Dilated Perivascular Spaces and Disease Severity in Patients With Huntington Disease.

Suk Tak Chan, Nathaniel D Mercaldo, Bernard Ravina, Steven M Hersch, Herminia D Rosas

Open access · hybridAbstract read
In one paragraph

Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Glymphatic Dysfunction, Brain Damage, and Clinical Disability in Spinocerebellar Ataxia Type 3.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The glymphatic system in Huntington's disease.Journal of Huntington's disease · 2025
    Review
  11. Diffusion along Perivascular Spaces as a Marker for Glymphatic System Impairment in Huntington's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Mild cognitive impairment in Huntington's disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Suk Tak ChanFrom the Athinoula A. Martinos Center for Biomedical Imaging (S.T.C., H.D.R.), Department of Radiology, and Department of Neurology (N.D.M., S.M.H., H.D.R.), Massachusetts General Hospital, Boston; Voyager Therapeutics (S.M.H.); and Praxis Medicines (B.R.), Cambridge, MA.ORCID 0000-0001-6627-3173
Nathaniel D MercaldoFrom the Athinoula A. Martinos Center for Biomedical Imaging (S.T.C., H.D.R.), Department of Radiology, and Department of Neurology (N.D.M., S.M.H., H.D.R.), Massachusetts General Hospital, Boston; Voyager Therapeutics (S.M.H.); and Praxis Medicines (B.R.), Cambridge, MA.
Bernard RavinaFrom the Athinoula A. Martinos Center for Biomedical Imaging (S.T.C., H.D.R.), Department of Radiology, and Department of Neurology (N.D.M., S.M.H., H.D.R.), Massachusetts General Hospital, Boston; Voyager Therapeutics (S.M.H.); and Praxis Medicines (B.R.), Cambridge, MA.
Steven M HerschFrom the Athinoula A. Martinos Center for Biomedical Imaging (S.T.C., H.D.R.), Department of Radiology, and Department of Neurology (N.D.M., S.M.H., H.D.R.), Massachusetts General Hospital, Boston; Voyager Therapeutics (S.M.H.); and Praxis Medicines (B.R.), Cambridge, MA.
Herminia D RosasFrom the Athinoula A. Martinos Center for Biomedical Imaging (S.T.C., H.D.R.), Department of Radiology, and Department of Neurology (N.D.M., S.M.H., H.D.R.), Massachusetts General Hospital, Boston; Voyager Therapeutics (S.M.H.); and Praxis Medicines (B.R.), Cambridge, MA. rosas@helix.mgh.harvard.edu.
Voyager Therapeutics (United States) · US

Funding

Huntington's Disease: Learning from ExtremesR01NS106384 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ROSAS, HERMINIA DIANA · 2018 to 2022
$7.6M
Understanding the Contribution of Altered Cerebrovascular Function to the Pathology and Clinical Symptoms of Huntington DiseaseR01NS114562 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HERMINIA Diana ROSAS · 2021 to 2026
$3.3M
6 · The paper itself

Abstract

objectiveTo quantify the percent volume of dilated perivascular space (PVS) in the subcortical forebrain in patients with early Huntington disease (HD) and to explore the relationship between PVS and disease severity.

methodsMRI scans were performed on 25 patients with HD and 23 healthy age-matched controls at Massachusetts General Hospital. The imaging data were analyzed with a novel algorithm to determine regional PVS volume. A fractional logistic regression analysis was used to quantify the association between regional percent PVS volume and (1) disease designation (HD or control) and (2) disease severity as assessed by normalized caudate volume.

resultsPatients with HD had the greatest percent volume of dilated PVS in the putamen (left putamen: odds ratio 2.06 [95% confidence interval (CI) 1.62-2.62], HD 3.27% [95% CI 2.83-3.78] vs controls 1.62% [95% CI 1.32-1.97],

conclusionsThe objective quantification of dilated PVS suggests that PVS burden is high, is associated with disease severity, and may affect the distribution and success of treatments administered either intrathecally such as antisense oligonucleotides or by intraparenchymal administration such as cell and gene therapies. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that increased dilated PVS is associated with worse HD severity. The study is rated Class II because of the cross-sectional design.

Indexed as

AdultCross-Sectional StudiesFemaleGlymphatic SystemHumansHuntington DiseaseImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedPutamenSeverity of Illness IndexWhite Matter

Identifiers

PMID33106388
PMCPMC8105900
OpenAlexW3094354461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.